Optimized dengue virus entry inhibitory peptide (DN81)

• US 8,541,377 B2
• Filed: 07/11/2008
• Issued: 09/24/2013
• Est. Priority Date: 07/13/2007
• Status: Active Grant

• Current Assignee: Florida Gulf Coast University Board of Trustees (State University System of Florida), University of Washington
• Original Assignee: Florida Gulf Coast University Board of Trustees (State University System of Florida)
• Inventors: Michael, Scott F., Isern, Sharon, Garry, Robert, Samudrala, Ram, Costin, Joshua, Jenwitheesuk, Ekachai
• Primary Examiner(s): GUDIBANDE, SATYANARAYAN R
• Application Number:
  US12/668,828
• Publication Number:
  US 20110112031A1
• Time in Patent Office: 1,901 Days
• Field of Search: None
• US Class Current: 514/21.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Claims

1. A synthetic peptide comprising:

an amino acid sequence presented as SEQ ID NO;

1.

2. The peptide of claim 1, wherein the peptide inhibits a class II viral envelope protein.

3. The peptide of claim 2, wherein the class II envelope protein is a dengue virus E protein.

4. The peptide of claim 1, wherein the peptide inhibits dengue virus virion:

cell fusion.

5. A pharmaceutical composition comprising the peptide of claim 1.

6. The pharmaceutical composition of claim 5, further comprising a biocompatible carrier.

7. The pharmaceutical composition of claim 6, wherein the biocompatible carrier is selected from the group consisting of saline, buffered saline, dextrose and water.

8. A method of treating dengue virus infection in a subject comprising the steps of:

administering a therapeutically effective amount of the peptide comprising the amino acid sequence presented as SEQ ID NO;

1 to a subject in need thereof.

9. The method of claim 8, wherein the peptide inhibits dengue virus virion:

cell fusion.

10. The method of claim 8, wherein the peptide is administered intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, orally or intranasally.

11. The method of claim 8, wherein the peptide is conjugated to a carrier molecule.

12. The method of claim 11, wherein the carrier molecule is human serum albumin (HSA).

13. The method of claim 10, wherein the peptide is administered to a mammal.